Actelion Ltd (ALIOF) 167.8200 $ALIOF 3 Dirt-Cheap

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actelion Ltd (ALIOF) 167.8200 $ALIOF

3 Dirt-Cheap Biotech Stocks To Buy
Todd Campbell, The Motley Fool - Motley Fool - Wed May 04, 8:17AM CDT
SOURCE: FLICKR USER ELLIOTT BROWN Sometimes stocks sell down to prices that look too good to be true, but just because a company appears cheap doesn't mean that its a good value. For a company to be a bargain that's really worth buying, there needs...
ENDP: 16.56 (-0.42), GILD: 83.89 (-0.97), MRK: 58.00 (+0.06), UTHR: 107.73 (-1.16)

Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved
Globe Newswire - Wed May 04, 5:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion's Annual General Meeting of Shareholders held in Basel, Switzerland - All Board proposals approved . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 28.78 (+0.07), UTHR: 107.73 (-1.16), AEGR: 1.47 (-0.11)

Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio
Globe Newswire - Thu Apr 21, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Very strong performance continues in the first quarter of 2016 - driven by outcome-based PAH portfolio . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Clovis Hits 52-week Low Post Rociletinib Briefing Documents
Zacks Equity Research - Zacks Investment Research - Mon Apr 11, 2:45PM CDT
Clovis Oncology's (CLVS) shares touched a 52-week low with the FDA raising concerns related to the lung cancer treatment, rociletinib, in its briefing documents.
EBS: 28.78 (+0.07), CLVS: 14.24 (-0.45), ANIK: 53.83 (-0.43)

Ionis Tanks, FDA Clinical Hold on IONIS-TTRRx Phase III Study
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 3:40PM CDT
Ionis Pharmaceuticals' (IONS) shares plunged 11% after the FDA placed a clinical hold on the phase III CARDIO-TTR study on IONIS-TTRRx.
BIIB: 242.03 (-3.03), GSK: 43.50 (+0.33), IONS: 24.48 (+0.06)

Intercept's (ICPT) Ocaliva Gets Favorable FDA Panel Vote
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 2:35PM CDT
Intercept Pharmaceuticals, Inc. (ICPT) announced that the FDA's Gastrointestinal Drugs Advisory Committee has voted unanimously in favor of the company's lead pipeline candidate, Ocaliva.
ARQL: 1.75 (-0.10), SCMP: 10.82 (-0.21), ICPT: 143.47 (-2.89)

Illumina Unveils BaseSpace Suite, Boosts Precision Medicine
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 12:55PM CDT
Illumina, Inc. (ILMN) recently launched its BaseSpace Informatics suite to facilitate precision medicine and genomics research.
ILMN: 138.67 (-2.06), AMAG: 24.04 (-0.56), ANIK: 53.83 (-0.43)

Seres Therapeutics (MCRB) in Focus: Stock Up 5.5% in Session
Zacks Equity Research - Zacks Investment Research - Fri Apr 08, 7:35AM CDT
Seres Therapeutics, Inc. (MCRB) was a big mover last session, as the company saw its shares rise around 6% on the day.
MCRB: 29.09 (-0.84)

Ironwood Slumps, Halts Development of Gastroparesis Drug
Zacks Equity Research - Zacks Investment Research - Wed Apr 06, 9:10AM CDT
Ironwood Pharmaceuticals (IRWD) plans to discontinue the development of IW-9179 for diabetic gastroparesis after unfavorable phase IIa study results; shares fall.
IRWD: 13.06 (-0.13), EBS: 28.78 (+0.07), AMAG: 24.04 (-0.56)

Actelion issues invitation to 2016 Annual General Meeting of Shareholders
Globe Newswire - Wed Apr 06, 12:01AM CDT
Actelion Pharmaceuticals Ltd / Actelion issues invitation to 2016 Annual General Meeting of Shareholders . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

AbbVie Up, Wins CHMP Backing for Humira's Expanded Use
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 10:20AM CDT
AbbVie Inc. (ABBV) announced that the EMA's CHMP has rendered an opinion in favor of expanding Humira's label in the EU.
EBS: 28.78 (+0.07), ABBV: 61.92 (-0.79), AMAG: 24.04 (-0.56)

Abeona Therapeutics (ABEO) Jumps: Stock Rises 6.4%
Zacks Equity Research - Zacks Investment Research - Tue Apr 05, 7:40AM CDT
Abeona Therapeutics Inc. (ABEO) saw its shares rise above 6% in the last trading session.
ABEO: 2.42 (-0.01)

Bristol-Myers Gets CHMP Backing for Opdivo's Expanded Use
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 3:10PM CDT
Bristol-Myers' (BMY) Opdivo gets CHMP backing for label expansion of Opdivo in combination with Yervoy for advanced (unresectable or metastatic) melanoma.
AMAG: 24.04 (-0.56), BMY: 73.78 (unch), ANIK: 53.83 (-0.43)

Regeneron, Sanofi Up, Eczema Drug Tops Phase III Studies
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 2:40PM CDT
Regeneron Pharmaceuticals (REGN) and Sanofi's atopic dermatitis candidate dupilumab scores in phase III studies; shares up.
AMAG: 24.04 (-0.56), SNY: 41.36 (-0.43), REGN: 359.61 (+1.11)

The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 8:30AM CDT
The Zacks Analyst Blog Highlights: Actelion, Mesoblast, Kindred Biosciences and CorMedix
CRMD: 1.88 (-0.16), MESO: 4.12 (-0.18), KIN: 3.64 (+0.09)

VIVUS (VVUS) in Focus: Stock Jumps 6.4% in Session
Zacks Equity Research - Zacks Investment Research - Mon Apr 04, 7:05AM CDT
VIVUS Inc. (VVUS) was a big mover last session, as the company saw its shares rise more than 6% on the day.
VVUS: 1.17 (-0.05)

4 Best Biotech Stocks of the First Quarter of 2016
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 9:03AM CDT
Don't miss these best biotech stocks of the first quarter of 2016.
CRMD: 1.88 (-0.16), MESO: 4.12 (-0.18), GILD: 83.89 (-0.97), SHPG: 186.63 (+0.62), AMGN: 154.27 (-0.01), BXLT: 46.02 (-0.18), KIN: 3.64 (+0.09)

Dr. Reddy's Acquires Anticancer Drug Rights from Eisai
Zacks Equity Research - Zacks Investment Research - Fri Apr 01, 8:40AM CDT
Dr. Reddy's Laboratories (RDY) announced that it has entered into a licensing agreement with Eisai Co., Ltd, Japan.
AMAG: 24.04 (-0.56), RDY: 52.18 (-0.81), XNPT: 7.07 (+0.05)

Jazz's Hepatic VOD Drug Defitelio Gains FDA Nod, Shares Up
Zacks Equity Research - Zacks Investment Research - Thu Mar 31, 3:40PM CDT
Jazz Pharmaceuticals' (JAZZ) shares gained 2.6% after the FDA approved the company's hepatic VOD drug Defitelio.
JAZZ: 138.98 (-2.06), SCMP: 10.82 (-0.21), ANIK: 53.83 (-0.43)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

TRUSTA Targets AI Inference's GPU Memory Squeeze Hard

Updated Category News Views 87

GPU scarcity has turned ordinary server parts into strategic assets, and TRUSTA is leaning right into that uncomfortable fact at SuperComputing 2026. The enterprise-storage brand under ADATA is pitching an upgraded AI Scaler Toolkit built around a fairly sensible premise: companies running large-language-model inference should not have to buy another armful of expensive...

Continue Reading
AI Gives CPA Firms a New Advisory Staffing Math Today

Updated Category News Views 26

Month-end just got a lot less comfortable for firms living on the clock. Netsurit and Southwestern Talent are pitching the Virtual CFO Platform as a way for CPA firms to turn machine-led analysis into advisory work without first building a costly bench of specialists. That is not a cute workflow tweak. It goes straight at the labor model that has kept plenty of accounting...

Continue Reading
BNY's December Conference Slot Merits a Careful Listen

Updated Category News Views 183

A 10:40 a.m. conference appearance can look like wallpaper on a market calendar, but BNY's scheduled December 9 discussion deserves more attention than that. Robin Vince, the chief executive, is set to speak at the Goldman Sachs Financial Services Conference in New York, and the company has plainly warned that the conversation may include forward-looking statements and...

Continue Reading
Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 123

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Vertex Extends Genomics Pact With $220M in Potential

Updated Category News Views 54

Eight years is long enough to separate a useful science partner from a glossy slide deck, and Vertex’s decision to add four more years with Genomics deserves attention. This is not a splashy acquisition, nor is it a clean revenue number investors can plug into next quarter’s model. It is a deeper commitment to the slow, expensive, wonderfully unforgiving business of...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 85

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 54

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
LEPAS AURA Signals a Sharper Design Bet for Future Cars

Updated Category News Views 31

A porcelain-smooth concept car is not a balance sheet, but it can tell you where a young automotive brand intends to spend its attention. LEPAS unveiled AURA in October at its first Global Elegant Lifestyle Week, presenting it as the brand's first global concept car and a fresh expression of its Leopard Aesthetics design language. That matters because AURA is plainly not...

Continue Reading
Autoliv's Omni Safety Award Is a Promising Early Signal

Updated Category News Views 68

Reclined car seats are becoming a real engineering headache, not some showroom gimmick, and Autoliv has put a marker down with Omni Safety™. The company received 2026 Automotive News PACE Pilot recognition for the system, which tackles occupant protection when people are sitting farther back than conventional vehicle safety designs assumed. That matters because...

Continue Reading
Knotch Bets Brands Need Answers, Not More Web Pages

Updated Category News Views 229

Pages are starting to look like expensive filing cabinets A website that cannot answer an agent may soon be expensive wallpaper. That is the blunt premise behind Knotch's Ace for Agents, launched Nov. 17, 2026, and frankly it lands because plenty of big companies have spent years piling pages atop pages until nobody can tell which claim is current. Knotch is pitching an...

Continue Reading

Top 5 Most Recently Viewed Articles

Desreta Jackson's New Show: A Journey of Healing and Legacy

Updated Category News Views 551

Desreta Jackson Unveils Groundbreaking Show This Fall Desreta Jackson, who captivated audiences through her memorable role as young Celie in Steven Spielberg's acclaimed film The Color Purple, is set to make her return to the limelight with the launch of The Desreta Jackson Show this fall. Produced by Desicon Pictures, the show seeks to ignite meaningful conversations...

Continue Reading
Clarios Unveils Ambitious Initiative to Transform U.S. Manufacturing

Updated Category News Views 354

Clarios Set to Revolutionize U.S. Manufacturing Landscape Clarios is embarking on an exciting journey to bolster American manufacturing, with plans to establish a cutting-edge technology campus focusing on advanced supercapacitor systems production. This initiative is part of a comprehensive $6 billion investment strategy aimed at strengthening domestic supply chains....

Continue Reading
Franchise Equity Partners Expands with Strategic Valvoline Deal

Updated Category News Views 274

Franchise Equity Partners Forms Strategic Partnership with Valvoline Franchise Equity Partners (FEP) is thrilled to announce a new strategic partnership with Valvoline Inc. This collaboration marks a significant milestone as FEP plans to acquire 38 Valvoline company-owned stores. The stores, located in various regions of Texas, will be transitioning to a newly established...

Continue Reading
New Found Gold Announces Successful Financing Round Closing

Updated Category News Views 183

Recent Financing Success of New Found Gold New Found Gold Corp. (TSXV: NFG) (NYSE-A: NFGC) is excited to share the successful closing of its second and final tranche in the bought deal financing, securing a remarkable C$63 million to advance its projects. This milestone marks a significant achievement for the Company, facilitating crucial developments in the exploration...

Continue Reading
Joby Aviation Surpasses Expectations in Q3 Financials

Updated Category News Views 194

Joby Aviation's Remarkable Growth in Q3 Joby Aviation, Inc. (NYSE: JOBY) has recently experienced a substantial surge in stock value, reflecting investor confidence following the release of its third-quarter earnings report. This report highlighted significant movements, particularly as it beat estimates on revenue, even though it faced a mixed assessment regarding its...

Continue Reading